221187-06-0Relevant academic research and scientific papers
HISTONE DEACETYLASE INHIBITOR AND PROCESS FOR PRODUCING THE SAME
-
, (2008/06/13)
HDAC inhibitors represented by formula (1) show strong inhibitory activity against various subtypes of HDACs. The compounds of the present invention find utility as pharmaceutical agents for treating or preventing diseases associated with HDAC 1, 4, and 6
Histone deacetylase inhibitors and process for producing the same
-
Page/Page column 12, (2008/06/13)
Compounds represented by formula (1) have strong inhibitory activity that is selective towards HDAC1 and HDAC4. Therefore, the compounds of the present invention are useful as pharmaceutical agents for treating or preventing diseases caused by HDAC1 and HDAC4.
Cyclic Tetrapeptides Bearing a Sulfhydryl Group Potently Inhibit Histone Deacetylases
Nishino, Norikazu,Jose, Binoy,Okamura, Shinji,Ebisusaki, Shutoku,Kato, Tamaki,Sumida, Yuko,Yoshida, Minoru
, p. 5079 - 5082 (2007/10/03)
(Equation presented) New inhibitors of histone deacetylase (HDAC) containing a sulfhydryl group were designed on the basis of the corresponding hydroxamic acid (CHAP31) and FK228. Their disulfide dimers and hybrids exhibited potent HDAC inhibitory activity in vivo with potential as anticancer prodrugs.
Cyclic tetrapeptide derivatives and medicinal use thereof
-
, (2008/06/13)
A cyclic tetrapeptide derivative represented by the general formula (I): wherein: R11, R12, R21and R22independently denote a monovalent group selected from hydrogen, a linear or branched alkyl group with 6 or less carbon atoms, benzyl group, 4-methoxybenzyl group, 3-indolylmethyl group, (N-methoxy-3-indolyl) methyl group, (N-formyl-3-indolyl)methyl group, etc.; R3denotes a divalent group selected from a linear chained hydrocarbon group with 3 or 4 carbon atoms, or the linear branched hydrocarbon group having a branched chain added to the chain, or a divalent group substituted with a heteroatom; R4denotes a divalent chained hydrocarbon group with4to6carbon atoms, or a divalent group derived from said hydrocarbon group by addition etc. of a branched chain on said chain; and a pharmaceutically acceptable salt thereof, or an analogous cyclic tetrapeptide derivative compound; as well as a histone deacetylase enzyme inhibitor, an MHC class-I molecule expression promoting agent and a pharmaceutical composition that comprise said cyclic tetrapeptide derivative as an effective ingredient.
